New Heart-Rhythm Drug Screen Tested
Early preclinical work suggests a refined hERG measure could better flag drugs that disrupt heart rhythm.
Updated on Nov. 4, 2026 in Heart Disease

Researchers William J. Crumb Jr. and Andrew G. Edwards published a study in the Journal of Pharmacological and Toxicological Methods testing whether a hERG potassium channel metric called IC10 can better predict drug-induced QT prolongation than the conventional IC50 approach. The work is aimed at drug developers screening candidate medicines for heart-rhythm safety.
Why it matters
QT prolongation is a drug-related change in the heart's electrical cycle that can raise the risk of dangerous arrhythmias, so screening for it is a standard part of drug safety testing. A more reliable predictive metric could help identify risky compounds earlier in development, which matters for anyone who takes medications affecting the heart.
This is a published methodological study comparing two hERG channel inhibition thresholds as predictors of drug-induced QT prolongation. The source does not report sample size, study duration, or quantified effect size, so the comparative performance claim remains unquantified here.
The players
Nova Research Laboratories, LLC
A research organization led by William J. Crumb Jr., involved in preclinical drug cardiac risk research.
Simula Research Laboratory
An Oslo, Norway-based research institution where Andrew G. Edwards serves as Chief Research Scientist, focused on computational physiology.
Organos
A Berkeley, California company where Andrew G. Edwards serves as COO, active in organ-related biomedical research.
The details
The hERG potassium channel plays a central role in repolarizing heart cells after each beat, and drugs that block it can lengthen the QT interval on an electrocardiogram. Conventional safety testing uses the concentration that halves channel activity (IC50), while this study evaluates whether the concentration causing just 10% inhibition (IC10) gives a more accurate early warning. The authors combined experimental electrophysiology with computational physiology modeling, a pairing intended to link lab measurements to whole-heart behavior.
Timeline
November 4, 2026: Press release on the publication issued via GlobeNewswire, datelined New Orleans.
Health Landscape
Current drug development relies on hERG IC50 measurements as an early screen for QT-prolonging risk before thorough QT trials. This study tests whether a lower-threshold IC10 metric could sharpen that early screen.
If you take medications known to affect heart rhythm, it is worth asking your prescriber whether your drug's QT risk has been assessed. Any questions about your own heart-rhythm safety are best discussed with your physician.
The takeaway
Better early screening for QT risk could help catch dangerous drug effects sooner in development. Anyone with a history of heart-rhythm problems should review their medication list with a clinician.
Further reading
For broader context on the condition this screening protects against, see our Heart Disease coverage.


